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The present study investigated a novel extended release system of promethazine hydrochloride (PHC) 
with acrylic polymers Eudragit RL100 and Eudragit S100 in different weight ratios (1:1 and 1: 5), and 
in combination (0.5+1.5), using freeze-drying and spray-drying techniques. Solid dispersions were 
characterized by Fourier-transformed infrared spectroscopy (FT-IR), differential scanning calorimetry 
(DSC), Powder X-ray diffractometry (PXRD), Nuclear magnetic resonance (NMR), Scanning electron 
microscopy (SEM), as well as solubility and in vitro dissolution studies in 0.1 N HCl (pH 1.2), double-
distilled water and phosphate buffer (pH 7.4). Adsorption tests from drug solution to solid polymers were 
also performed. A selected solid dispersion system was developed into capsule dosage form and evaluated 
for in vitro dissolution studies. The progressive disappearance of drug peaks in thermotropic profiles of 
spray-dried dispersions were related to increasing amount of polymers, while SEM studies suggested 
homogenous dispersion of drug in polymer. Eudragit RL100 had a greater adsorptive capacity than 
Eudragit S100, and thus its combination in (0.5+1.5) for S100 and RL 100 exhibited a higher dissolution 
rate with 97.14% drug release for twelve hours. Among different formulations, capsules prepared by 
combination of acrylic polymers using spray-drying (1:0.5 + 1.5) displayed extended release of drug for 
twelve hours with 96.87% release followed by zero order kinetics (r2= 0.9986).
Uniterms: Promethazine hydrochloride/extended release. Drugs/extended release. Eudragit RL100. 
Eudragit S100. Acrylic polymers. Spray drying/pharmacotechnics. Freeze drying/pharmacotechnics. 
Extended realease/pharmacotechnics. Pharmaceutical formulations/evaluation.
O presente trabalho compreendeu estudo de um novo sistema de liberação prolongada de cloridrato de 
prometazina (PHC) com polímeros acrílicos Eudragit RL100 e Eudragit S100 em diferentes proporções 
em massa (1:1 e 1:5) e em combinação (0,5+1,5), utilizando técnicas de liofilização e de secagem 
por aspersão As dispersões sólidas foram caracterizadas por espectrofotometria no infravermelho por 
transformada de Fourier (FT-IR), calorimetria diferencial de varredura (DSC), difratometria de raios X 
(PXRD), Ressonância Magnética Nuclear (RMN), microscopia eletrônica de varredura (SEM) e, também, 
por estudos de solubilidade e de dissolução in vitro em HCl 0,1 N (pH 1,2), água bidestilada e tampão 
fosfato (pH 7,4). Realizaram-se, também, testes de adsorção da solução do fármaco nos polímeros sólidos. 
Desenvolveu-se sistema de dispersão sólida exclusiva dentro das cápsulas, que foi avaliado por meio de 
estudos de dissolução in vitro. Relacionou-se o desaparecimento progressivo de picos do fármaco em 
perfis termotrópicos de dispersões secas por spray à quantidade aumentada de polímero, enquanto os 
estudos de SEM sugeriram  dispersão homogênea do fármaco no polímero. O Eudragit RL100 apresentou 
maior capacidade de adsorção do que o Eudragit S100 e, dessa forma, a combinação de (0,5+1,5) para 
S100 e para  RL100 mostrou taxa de dissolução maior, com liberação de 94,17% de fármaco em 12 horas. 
Entre as várias formulações, as cápsulas preparadas pela combinação de polímeros acrílicos utilizando 
secagem por aspersão (0,5+1,5) apresentou liberação prolongada do fármaco em 12 horas, com 96,78% 
de liberação, seguindo cinética de ordem zero (r2 = 0,9986)
Unitermos: Cloridrato de prometazina/liberação prolongada. Fármacos/liberação prolongada. Eudragit 
RL100. Eudragit S100. Polímeros acrílicos. Secagem por aspersão/farmacotécnica. Liofilização/
farmacotécnica. Formulações farmacêuticas/avaliação.
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INTRODUCTION
The solid dispersion approach is commonly used to 
improve the dissolution properties of poorly water-soluble 
drugs using hydrophilic polymeric carriers as dispersing 
agents. More recently, several studies on solid dispersions 
have been carried out using water-insoluble carriers to pro-
duce sustained release pharmaceutical forms of freely wa-
ter soluble drugs (Zijlstra et al., 2007; Drooge et al., 2004; 
Nagarsenker et al., 2000). For this goal, different types 
of polymethacrylates (Eudragit) have been considered. 
The most interesting among acrylic polymers are highly 
permeable Eudragit RL and low permeable Eudragit RS. 
Both are neutral copolymers of poly ethylacrylate (me-
thyl methacrylate and trimethyl aminoethyl methacrylate 
chloride), and are insoluble in water and digestive juices, 
though both swell and are permeable. Extended-release 
systems are the methods that can achieve therapeutically 
effective concentrations of drugs in systemic circulation 
over an extended period of time. Several studies (Thybo 
et al., 2008; El-badry et al., 2006; Torrado et al., 1996; 
Drooge et al., 2005) and (Mangal et al., 1997; Mooter 
et al., 2001; Miyazaki et al., 2006; Ammar et al., 1997; 
Hirasawa et al., 2003) used the solid dispersion method 
for this purpose. A combination of solid dispersion and 
extended-release is one of the attractive approaches since 
supersaturation of the drugs can be achieved by employing 
the solid dispersion technique (Ozeki et al., 1995). In the 
present study, Eudragit RL100 and Eudragit S100 have 
been used as retardants to prepare a novel extended-release 
system of highly water soluble medicine promethazine 
hydrochloride using spray-drying and freeze-drying 
techniques in order to extend their dissolution rates. A 
selected solid-dispersion system was further subjected 
to capsule preparation in order to study the feasibility of 
incorporating solid-dispersion for formulation as a drug 
delivery system.
MATERIALS AND METHODS
Promethazine hydrochloride (PHC) was supplied 
by Seimens Laboratory, India. Eudragit S100 (S100) and 
Eudragit RL100 (RL100) were donated by Rohm Pharma, 
Germany. Lactose, sodium starch glycolate (Explotab), and 
silicon dioxide (Aerosil) were purchased from Merck India 
Limited, Mumbai. Other chemicals were of analytical grade. 
Double-distilled water was used throughout the study.
Preparation of Freeze-dried solid dispersions
PHC and Eudragit polymers were dissolved se-
parately in absolute ethanol. The mixture formed by 
adding polymer solution to the PHC solution, was frozen 
overnight in a petri dish at -45 oC and lyophilized in a 
freeze-dryer (model Lyph-Lock 12L) at -45 oC for forty-
eight hours. Secondary drying was carried out at room 
temperature. The freeze-drying process was run until a 
dry, solid dispersion of drug was obtained. The obtained 
dispersion was then screened through a 40-mesh standard 
sieve and stored in desiccators (Govindrajan et al., 2004).
Preparation of spray-dried solid dispersions
Polymers were dissolved in a sufficient amount of 
ethanol: water 50% (v/v) solution and PHC was added 
under continuous stirring. The resulting mixture was 
TABLE I - Formulation of PHC and Eudragit solid dispersion systems
Method of Preparation Type of Polymer Weight Ratio (Drug: Polymer) Formulation code
Physical mixing
Freeze drying
Spray drying
Physical mixing
Freeze drying
Spray drying
Physical mixing
Freeze drying
Spray drying
Physical mixing
Freeze drying
Spray drying
Physical mixing
Freeze drying
Spray drying
RL100
RL100
RL100
RL100
RL100
RL100
S100
S100
S100
S100
S100
S100
S100+RL100 (0.5+1.5)
S100+RL100 (0.5+1.5)
S100+RL100 (0.5+1.5)
1:1
1:1
1:1
1:5
1:5
1:5
1:1
1:1
1:1
1:5
1:5
1:5
1:2
1:2
1:2
PM1RL
FD1RL
SD1RL
PM5RL
FD5RL
SD5RL
PM1S
FD1S
SD1S
PM5S
FD5S
SD5S
PM2SRL
FD2SRL
SD2SRL
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stirred for twenty-four hours at room temperature and 
the obtained solution was subsequently spray-dried 
(LabPlant SD-05), under the following conditions: air 
flow rate – 50 m3/h; atomizing air pressure – 1×105 
Pa; inlet temperature of 160° C, outlet temperature 
of 85 °C; flow rate of the solution at 400 ml/h. The 
obtained product was sieved through a 40-mesh stan-
dard sieve and stored in desiccators. Physical mixtures 
(PMs) with corresponding weight ratios were prepared 
by triturating the drug and polymer in a glass mortar 
(Table I). The powders were then sifted (150 mm sieve) 
and stored in desiccators. 
Determination of Drug Content
Ten milligrams of the solid dispersion was accurate-
ly weighed and diluted up to 10 mL with double distilled 
water. From this, a 1ml of sample was withdrawn and di-
luted up to 10 mL with double-distilled water and assayed 
spectrophotometrically for promethazine HCl at 249 nm 
using a suitably constructed calibration curve in double-
distilled water. The studies were conducted in triplicate 
(Pignatello et al., 2002).
Solubility Measurements and Adsorption Studies
The solubility of solid dispersions was studied in 
0.1 N HCl (pH 1.2), double-distilled water and phosphate 
buffer (pH 7.4). The samples were subsequently allowed to 
equilibrate at 37 ± 0.1 °C in a mechanical shaker (HICON, 
India) for twenty-four hours. The samples were filtered, 
suitably diluted and analyzed spectrophotometrically 
(Shimadzu 1700, Japan) (Cui et al., 2003). For adsorption 
studies, the drug was dissolved in phosphate buffer pH 7.4 
(50 mL). A ten-fold weight of ground S100 or RL100 was 
added to the solution, and the mixture was magnetically 
stirred at room temperature for fifteen days. Samples were 
periodically drawn, filtered, diluted and assayed spectro-
photometrically (Shimadzu, Pharmaspec 1700, Japan) at 
249 nm (Esclusa-Diaz et al., 2003).
Preparation of Capsules
A SD2SRL solid dispersion was developed into 
capsule dosage forms according to the formulations lis-
ted in Table II. Lactose was used as the capsule diluent, 
while various concentrations of a disintegrant, Explotab 
(2%, 5% and 8%), were used in capsule formulations. 
Silicon dioxide (Aerosil) was used as a glidant in the 
capsules. A control capsule containing 0% Explotab was 
also prepared. 
Observation of Dissolution Behavior of PHC from 
Solid Dispersions and Capsules
The dissolution behavior of PHC from pure PHC 
powder or its FDs, SDs and PMs was performed using 
a USP XXVII Apparatus I in 900 mL of 0.1 N HCl 
(pH 1.2) , double-distilled water, and phosphate buffer 
(pH 7.4) at an agitation rate of 100 rpm (USP, 2005). 
The temperature of the medium was maintained at 
37 ± 0.5 °C. Seventy-five milligrams of drug, or its 
equivalent, of the prepared dispersions were packed 
in transparent gelatin capsules and analyzed for dis-
solution. Capsules prepared with the selected solid-
dispersion system were also analyzed for dissolution. 
A 5.0 mL sample was withdrawn at specific hourly time 
points (beginning at zero) over a twelve hour period and 
replaced immediately with an equal volume of fresh 
dissolution medium to maintain a constant volume. 
The aliquot samples were filtered and the drug con-
centrations were determined spectrophotometrically at 
249 nm. The drug release kinetics were investigated by 
fitting the dissolution data to PCP Disso V 2.0 software 
(Pune, India).
Disintegration studies
Disintegration studies of the PHC-controlled release 
solid-dispersion capsules were performed by a USP-type 
disintegrator (K.S.L. Engineering Co., Ltd., USP type, 
Thailand) according to USP XXIII, using distilled water 
as medium. Average disintegration time of a capsule for-
mulation was obtained from six capsules.
FTIR spectroscopy
IR spectra of pure drug and polymers, and of freeze-
dried solid dispersion, spray-dried solid dispersions and 
physical mixtures, were obtained with an FTIR spectro-
photometer, (Shimadzu 8201 PC) using KBr disks (about 
10 mg sample for 100 mg drug KBr). The scanning range 
used was 4000 to 400 cm-1 at a scan period of one minute 
(Huang et al., 2008).
TABLE II - Composition of solid dispersion capsules
Formulation F1 F2 F3 F4
SD2SRL (mg) 124.08 124.08 124.08 124.08
Lactose (mg) 287.52 280.32 270.22 261.12
Explotab® (%) - 2 5 8
Aerosil® (%) 0.5 0.5 0.5 0.5
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Differential scanning calorimetry
Thermal analysis was performed on the drug, freeze-
dried solid dispersion, spray-dried solid dispersions, phy-
sical mixtures and Eudragit polymers using a PERKIN 
– ELMER DSC-7. Samples (10-15 mg) were weighed and 
sealed into 40μL aluminium pans. DSC runs were conduc-
ted over a temperature range of 70 °C to 250 °C at a rate of 
10 °C/minute in a nitrogen atmosphere (Law et al., 2001).
X-ray powder diffractometry
Diffraction patterns of physical mixtures, drug, 
freeze-dried solid dispersion, spray-dried solid dispersions 
and Eudragit polymers were recorded with a PW 3040/60 
X’ Pert PRO (Netherland). A voltage of 40kV and a current 
of 30 mA for the generator were used, with Cu as the tube 
anode material. The solids were exposed to Cu-K
α
 radia-
tion (α1=1.54060 Å and α2=1.54439 Å, with a α1/α2 ratio 
of 0.5), over a range of 2θ angles from 10 °C to 30 °C, at 
an angular speed of 1o (2θ) per minute (Law et al., 2001).
1H NMR spectroscopy
To determine the nature of proton or protonated 
groups in the PHC and polymeric dispersions of PHC, the 
1H NMR spectrum in CDCl
3
 were recorded on a Bruker 
Avance 400, FT-NMR spectrometer, 300 MHz, using 
TMS as an internal standard, and the chemical shift (δ) 
was recorded in ppm (Zajc et al., 2005).
Scanning electron microscopy
The morphology of solid dispersion particles was 
characterized by scanning electron microscopy using LEO 
435 VP, UK. Solid dispersions were fixed on supports 
with carbon glue and coated with gold using a gold sputter 
model in a high vacuum evaporator. Samples were then 
observed with scanning electron microscopy (WU et al., 
2008).
Stability studies
A three-month accelerating condition stability test 
was carried out after preparation by which solid disper-
sion capsules were kept in an oven at a temperature of 
40  ± 1 °C and a relative humidity of 75%. The release 
profiles and drug content of the capsules were determined 
at the end of one, two and three months, respectively, and 
then compared with that of freshly prepared solid disper-
sion capsules (Mura et al., 1999).
RESULTS AND DISCUSSION
Determination of Drug Content
The actual drug content of solid dispersion systems 
were estimated in the range of 13.06 ± 0.001% to 
47.98 ± 0.001% (Table III). The drug content was found 
to be uniform in all solid dispersions and was in good 
agreement with theoretical drug content.
TABLE III - Drug Content and Model-Independent Parameters of PHC Solid Dispersions
S. No. Formulations Drug Content* (%) t
50%*
(h)
t
plateau
%DE
(0-12 h)
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
PM1S
SD1S
FD1S
PM5S
SD5S
FD5S
PM1RL
SD1RL
FD1RL
PM5RL
SD5RL
FD5RL
PM2SRL
SD2SRL
FD2SRL
47.98± 0.001
45.45 ± 0.001
47.17 ± 0.002
15.56± 0.002
13.06 ± 0.001
13.22 ± 0.001
50.00 ± 0.001
41.73± 0.001
47.16 ± 0.002
15.80 ± 0.002
13.33 ± 0.001
13.06 ± 0.001
30.21±0.014
29.88±0.011
27.23±0.52
1.0
2.0
2.0
3.0
3.0
3.5
2.0
2.5
2.0
4.50
5.0
4.75
5.25
6.0
5.75
6.0
4.0
5.0
10.0
9.0
6.0
6.0
9.0
7.0
12.0
12.0
12.0
12.0
12.0
12.0
58.12
53.44
30.21
63.85
56.21
49.74
63.22
66.78
55.89
65.42
76.22
60.88
69.56
81.02
66.23
*Zero order kinetics used for t50% measurement; Values of ED are different because this depends on % of released PHC after 12 
hours; *Average of three determinations
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Solubility Measurements and Adsorption Studies
The solubility of PHC in 0.1 N HCl (pH 1.2), double-
distilled water and phosphate buffer (pH 7.4) was found to be 
590.0 mg/mL, 557.7 mg/mL and 554.3 mg/mL respectively. 
The results revealed that the magnitude of the drug’s aqueous 
solubility can be decreased using methacrylate copolymers 
(Fig. 1). It was interesting to note that the magnitude of decre-
ased solubility in physical mixtures was quite similar to that 
of solid dispersions, indicating that preparation conditions 
used to obtain solid dispersions did not ultimately induce 
either polymorphic changes or amorphization of drug mo-
lecules. However, increasing the drug to polymer ratio from 
1:1 to 1:5 exhibited an approximately two-fold decrease in 
magnitude of drug solubility in each medium irrespective of 
the preparation method. The behavior of physical mixtures 
thus indicated that a dilution effect of drug microcrystal wi-
thin the polymer network is mainly responsible for changes 
observed during solubility studies. Among all solid disper-
sions, SD2SRL had a greater capacity to retard the solubility 
of PHC, i.e., 3.19 mg/mL, 3.01 mg/mL and 2.41 mg/mL in 
0.1 N HCl (pH 1.2), double-distilled water and phosphate 
buffer (pH 7.4) respectively. The rank order of decrease in 
solubility was as follows: 0.1 N HCl (pH 1.2), double-distilled 
water, phosphate buffer (pH 7.4) (Figure 1). This was due 
to the fact that PHC possesses a basic group that becomes 
protonated at acidic pH, making the drug readily soluble. To 
further evaluate the affinity between the tested molecules and 
polymers, adsorption of the drug onto S100 and RL100 was 
calculated quantitatively. The ability of Eudragit polymers 
to adsorb basic drug from a solution was characterized at 
pH 7.4. In adsorption studies, RL100 had greater adsorptive 
capacity than S100 (Figure 2) because of its greater number 
of quaternary ammonium functions, which act as the activity 
sites for electrostatic interactions in solution (Dollo et al., 
1996; Saenger et al., 1998).
Release mechanism of Single carrier solid 
dispersions
The dissolution profiles of PHC and solid disper-
sions are presented in Figure 3. The dispersions of drug 
in polymer matrices strongly influenced their dissolution 
rate, which appeared slower and more gradual than that 
of pure drug. At pH 7.4, solid dispersions were found 
to extend drug release up to twelve hours because of 
a decrease in solubility as compared to other media. 
The presence of the polymer also reduced the massive 
initial drug dissolution observed with pure PHC. On 
the contrary, the drug dissolution rate was markedly re-
tarded from both the freeze-dried and spray-dried solid 
dispersions. Retarding effect on PHC dissolution was 
dramatically more evident for the spray-dried system. 
After eight hours, the percentage of dissolved drug from 
the spray-dried solid dispersions was only about 60% in 
contrast to the freeze-dried solid dispersions which was 
nearly 80%. In addition, it was clearly observed that the 
drug release profile of the spray-dried solid dispersions 
consisted of a very slow release in the first stage (up to 
one hour) and a faster release in the second phase. In the 
first stage, the PHC seems to be released according to 
zero-order kinetics. It was also clear from the results that 
the dissolution rate of SD5S was much lower than that of 
SD5RL. These results might be attributed to the higher 
swelling and permeation characteristics of RL100 at pH 
1.2- 7.4, and due to its permeability, diffusion occurs. 
At the same time, Eudragit S100 is soluble in a buffer 
solution above pH 7.0 and remains intact throughout the 
dissolution period. Thus the release rate of the drug from 
FIGURE 1 - Equilibrium solubility study of PHC and its solid 
dispersions in 0.1 N HCl (pH 1.2), Double distilled water, 
Phosphate buffer (pH 7.4)
FIGURE 2 - Adsorption pattern of PHC onto RL100 and S100 
Particles from pH 7.4 Phosphate buffer
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Eudragit S100 spray-dried solid dispersions is less than 
that from Eudragit RL100 spray-dried solid dispersions. 
Increasing the drug-to-polymer ratio (from 1:1 and 1:5) 
dramatically increased the release time (t
50% 
values from 
1-3.5 hours to 2-5.0 hours) as well as the percentage of 
released PHC. However, t
50% 
values also seemed to be 
dependent on the type of polymer, as evidenced by the 
fact that SD1S and SD1RL showed t
50% 
values of two 
and two and a half hours whereas SD5S and SD5RL 
showed t
50% 
values of three and five hours respectively. 
This indicated that the polymer properties affected the 
drug release behavior more prominently when used at 
higher ratios in the solid dispersions. As DE takes into 
account the entire dissolution profile as a whole, as 
opposed to t
50% 
values, this approach employed a more 
realistic and meaningful method of comparison as well 
as interpretation of in vitro dissolution data for various 
formulations (Chowdary et al., 2006). The dissolution 
efficiency throughout the entire dissolution period 
(DE
0—12 h
) showed that dissolution of the drug from its 
spray-dried solid dispersions with RL100 was eviden-
tly higher than from systems containing S100 (Table 
III). Freeze-dried solid dispersions containing S100 at 
higher drug to polymer ratio (FD5S) was also able to 
slow down the diffusion rate of drug (Figure 3). The 
dissolution data showed that the difference in release 
profiles was mainly influenced by the type and amount 
of polymer used. However, when the type and amount 
of polymer was similar, the difference in release profile 
(as in the release pattern of SD5RL and FD5RL) can be 
better explained based on the different morphological 
states of drug within the polymer matrix. When PHC 
was freeze-dried, drug–polymer multi-dispersion was 
possible. This is characterized by embedding the drug 
particles within the polymer matrices, wherein the exact 
uniform distribution of the drug within the polymer ma-
trices is difficult with a consequent aggregation of drug 
and polymer in discrete domains resulting in undesirable 
release profiles. After twelve hours of dissolution, none 
of the solid dispersions prepared with 1: 1 ratios were 
able to retard the drug release significantly. However, 
at 1:5 ratios, the spray-dried solid dispersions displayed 
more sustained and gradual dissolution as compared 
to other solid dispersions with S100 and RL100. Such 
behavior might be due to the fact that the dissolved 
drug was re-adsorbed back onto the polymer particles 
resulting in subsequent saturation of the binding sites on 
the polymer backbone, and evidenced by a shorter time 
to reach plateau (t
plateau
) in the dissolution curves. The 
phenomenon is proportionally related to the amount of 
polymer present in solid dispersions. 
Release mechanism of solid dispersions with 
combined carriers
Incorporation of the drug with a mixture of anionic 
polymer Eudragit S100 and the zwitterionic polymer Eu-
dragit RL100 (SD2SRL) in herit? to the drug dissolution 
rate, which is clearly lower than that of the drug, but still 
higher than that of SD5RL and SD5S (Figure 3). This is 
also obvious from the data of the dissolution efficiency of 
these systems calculated from the amount of drug dissol-
ved through the entire dissolution run. Studies revealed 
that t
50% 
values of PM2SRL, SD2SRL and FD2SRL were 
5.25, 6.0 and 5.75 hours respectively (Table III). This in-
dicated that when used in combination, Eudragit polymers 
customize the release profile of drug. 
In order to identify the interactive effect, the dis-
solution data for the prepared solid dispersions of PHC 
were subjected to multiple regressions, using a statistical 
computer program. The dissolution profile of prepared 
PM2SRL, FD2SRL and SD2SRL solid dispersions were 
analyzed by linear regression. The kinetics treatment of 
SD2SRL showed that the release of drug followed zero 
order kinetics (r2 = 0.9812). Korsemeyer and Peppa’s 
equation gave value of n = 0.5050, indicating that the drug 
was released by Fickian diffusion.
Development of PHC-controlled release capsules
The prepared SD2SRL solid dispersion was deve-
loped into a capsule dosage form. A water-soluble diluent 
lactose was selected because of its hydrophilicity, which 
would impart little dissolution-retarding effect to the solid 
dispersion with packing into capsules. The SD2SRL solid 
dispersion was chosen as a model of solid dispersion to be 
FIGURE 3 - Comparative Dissolution Profiles of PHC and Solid 
Dispersions in Phosphate buffer pH 7.4.
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developed into a capsule formulation because its dissolu-
tion profile lay above the profiles of SD5RL and FD5RL 
solid dispersions. The effect of disintegrant Explotab was 
studied by varying its concentration (0%, 2%, 5%, and 8%) 
in the capsule formulations. The goal of the study was to 
develop a solid dispersion capsule having the closest dis-
solution to a solid dispersion powder being encapsulated. 
Therefore, a dissolution parameter indicating characteris-
tics of the dissolution profile had to be established.
Figure 4 illustrates dissolution profiles of the PHC-
controlled release, solid dispersion capsules as compared 
to that of the solid dispersion powder. Table IV shows the 
r2 values (Correlation coefficients) of zero order, first order 
and Korsemeyer Peppas equation for SD2SRL solid dis-
persion and capsules from two to twelve hours. First order 
and Peppas model were found to yield a smaller r2 than 
the zero order model. Therefore, the dissolutions of solid 
dispersion powder and capsules were found to follow zero 
order kinetics, rather than the first order or peppas models. 
As shown in Figure 4, the capsules containing 5% Explo-
tab exhibited a similar dissolution profile to solid disper-
sion powder. The dissolution profiles of the capsules with 
0% and 2% Explotab were comparable, and the dissolution 
profiles of the capsules of 5% and 8% Explotab were simi-
lar. Since the capsule of 8% Explotab showed the fastest 
dissolution, followed by the capsules of 5%, 2% and 0% 
Explotab, respectively, it was the prime target of capsule 
formulation development. Thus, increasing the Explotab 
concentration resulted in faster capsule dissolution. The 
capsules of 0% Explotab provided less drug dissolution 
than did the solid dispersion powder. Consequently, the 
incorporation of solid dispersion powder into capsules 
using lactose as diluent, resulted in less drug dissolution. 
The use of the disintegrant Explotab in the capsule was 
proven to help in restoring drug dissolution; however, an 
adequate concentration of the disintegrant was needed.
Disintegration times (DTs) of PHC-controlled release 
solid dispersion capsules are shown in Table 4, and ranged 
from 1.91 to 3.54 minutes. Since lactose was a water-soluble 
diluent, it provided no disintegration-retardation effect. All 
of the capsule formulations provided similar dissolution 
profiles during their initial stages of drug dissolutions and 
the capsule disintegration times were therefore not res-
ponsible for the differences in capsule dissolutions. As the 
capsules disintegrated, they yielded small coarse powder 
agglomerates, which could pass through the 10-mesh sieve 
of the disintegrator within a short period of time. The coarse 
agglomerates then disintegrated further into fine powders. 
The effect of Explotab as a disintegrant was not significant 
in the initial stage of capsule disintegration. However, its 
influence was more significant in the latter stage of powder 
agglomerate disintegration. Faster disintegration of the po-
wder agglomerate resulted in faster drug dissolution owing 
to a greater surface area available for the dissolution pro-
cess. This was responsible for the faster capsule dissolution 
at higher Explotab concentration in the capsule.
FTIR Spectroscopy
The above-mentioned results show a strong interac-
tion between the drug and acrylic polymers, suggesting the 
formation of a real solid dispersion by the spray-drying 
method. FTIR spectroscopy was used in order to confirm 
TABLE IV - Model fitting parameters and Disintegration Time of solid dispersion powder and capsules
Preparation Explotab® (%) r2 DT ± SD (min.)
Zero order First order Diffusion control
SD2SRL - 0.9812 0.9230 0.9337 -
F1 0 0.9941 0.8622 0.8875 3.54 ± 0.26
F2 2 0.9688 0.8633 0.8711 2.94 ± 0.11
F3 5 0.9898 0.8152 0.8823 2.12 ± 0.14
F4 8 0.9986 0.8895 0.8941 1.91± 0.22
Level of significance (p) of correlations = 5%.
FIGURE 4 - Dissolution Profiles of the SD2SRL Extended 
Release Solid Dispersion Capsules as Compared to the Profile 
of the Solid Dispersion Powder
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this assumption. For PHC, the IR stretching band of ter-
tiary amine around 1020 to 1250cm-1 (Figure 5) was still 
visible in physical mixtures, suggesting that there was no 
interaction between PHC/S100+RL100 in physical mix-
tures, while it completely disappeared in corresponding 
spray dried solid dispersions. This resulted in a broad 
band as well as altered stretching and bending vibrations. 
This result suggested the possibility of intermolecular 
hydrogen bonding between PHC and Eudragit polymers 
in spray-dried solid dispersions. These interactions were 
made while the molecules were in solution; when the 
distances between the molecules were so small that asso-
ciation between the functional groups is possible. Since 
in freeze-dried solid dispersion, FTIR spectrum showed 
no significant band modifications, we were able to con-
firm the hypothesis that this method does not give a true 
dispersion of PHC.
Differential scanning calorimetry
The solid dispersion systems were analyzed by me-
ans of DSC to detect possible altered thermal properties 
with regard to the pure substances. When guest molecules 
are incorporated in polymer matrix at 1:0.5 + 1.0 (Drug: 
S100+RL100) weight ratios, their melting points gene-
rally shift to a different temperature or disappear within 
the temperature range of pure drug. The DSC curves 
of PHC, a combination of Eudragit polymers (0.5+1.0, 
S100+RL100), and the respective drug carrier combina-
tions are shown in Figure 6. The thermal curve of PHC 
indicated its crystalline anhydrous state with a characte-
ristic endothermic fusion peak at 239 °C. The Eudragits 
thermogram displayed a very broad endothermic peak at 
210 °C due to the fusion process. The appearance of two 
endothermic peaks corresponding to the fusion of both 
components, and to the dehydration of polymers, was 
also evident in the thermogram of the physical mixture 
- as if this DSC curve was the superposition of those of 
the components analyzed separately. The shape and area 
of the PHC melting peak was unaffected by the blending 
with Eudragit polymers, therefore, the drug maintained 
its original crystallinity in the physical mixture. Consi-
dering the freeze-dried system, the two characteristic 
endothermic peaks of PHC were also observed (not com-
pletely suppressed). However, the thermal profile of the 
freeze-dried product was slightly different from that ob-
tained for the physical mixture, which was characterized 
by a sharp and definite endothermic effect in the region 
of the PHC melting endotherm. Some reduction of area, 
broadening and small downshift of the peak temperature 
of PHC melting endotherm (239 °C) was observed in 
the freeze-dried product. Since the freeze-dried product 
contains the same quantities of PHC and Eudragit poly-
mers present in the physical mixture, the reduction of 
the drug melting peak is not a result of a dilution effect. 
That behavior may be explained by better dispersion of 
the PHC microcrystals in the Eudragit polymers, or could 
be ascribed to some drug-polymer interactions. Although 
the PHC endothermic peak was partially reduced, the 
presence of this peak indicates that a true dispersion was 
not achieved by this preparation method. Almost com-
plete disappearance of the drug endothermic peak was 
found in the spray-dried preparation. The absence of the 
PHC fusion peak indicated the existence of interactions 
between the drug and Eudragit polymers in the solid 
state, and may be considered a strong indicator of the 
formation of real dispersions. The dispersion of PHC in 
matrix of Eudragit polymers S100 + RL100 (0.5 + 1.0) 
at 1: 2 weight ratios resulted in complete suppression of 
the drug fusion peak, suggesting possible solid solution 
of drug in polymer. 
X-Ray Diffractometry
X-Ray diffraction studies were performed to exa-
mine the crystallinity and provide further evidence of 
dispersion formation. The analysis of the X-ray powder 
FIGURE 5 - FT-IR Spectra of PHC, PM2SRL and SD2SRL.
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diffraction patterns of Eudragit solid dispersion systems 
is a powerful and very thoroughly assessed method for 
the characterization of solid dispersions in the solid 
state. Significantly different X-ray diffraction patterns 
are to be expected if solid dispersion is formed, since 
crystal structure will change. The X-ray diffraction pat-
terns of PHC, Eudragit polymers and the corresponding 
solid dispersion systems are represented in Figure 7. 
The diffractograms of PHC exhibited a series of sharp 
and intense diffraction peaks, which are indicative of 
their crystallinity. The diffraction pattern of the physical 
mixture was found to correspond exactly to the simple 
sum of the raw materials’ diffractograms, indicating the 
presence of PHC in the crystalline state. The freeze-
dried systems showed, with respect to the diffraction 
patterns of the starting materials, the broadening and 
the disappearance or intensity diminution of some PHC 
diffraction peaks. These findings suggest the presence 
of a new solid phase with a lower degree of crystallinity, 
which could be created by the molecular interaction 
of the host Eudragit polymers and the guest PHC. The 
spray-dried compound presented a completely diffu-
sed diffraction pattern, with the disappearance of the 
characteristic peaks of PHC, reflecting the amorphous 
nature of this solid dispersion system. This is direct 
proof of the formation of a new solid phase, and can be 
considered a very probable indication of the dispersion 
formation between PHC and Eudragit S100 + RL100 
in the solid state.
1 H NMR spectroscopy
FTNMR (1H-NMR) spectrum of PHC (Figure 8) 
showed chemical shift of 2.582 ppm (N (CH
3
)
2
) while 
in SD2SRL solid dispersion chemical shift was 2.697 to 
2.745 ppm (N–(CH
3
)
2
). This supported the possible hydro-
gen bonding between drug and polymer. There seemed to 
be a possible interaction between functional groups of drug 
and polymer due to hydrogen bonding based on FT-IR and 
FT-NMR but this effect was considered to be superficial 
since the drug kept its chemical structure and potency. No-
netheless, issues such as effect of type and concentrations 
of polymer on matrix structure of solid dispersions were 
of great significance from the dissolution viewpoint. The 
physical state of the drug in the polymer matrices, as well 
as electrostatic interaction between drug and ammonium 
groups present in the polymer backbone, contributed to 
possible saturation of binding sites, consequently leading 
to modification of release profiles. However, the results 
again emphasized that a low drug-to-polymer ratio is not 
sufficient for preparing useful delivery systems since strong 
interactions between them do not allow a significant release 
of drug, either in acidic or mid alkaline dissolution media.
Scanning electron microscopy
The shape and surface morphology of PHC, Eudragit 
polymers and the solid dispersion systems are presented in 
FIGURE 6 - Comparative DSC Thermograms of Pure drug, 
polymers, PM2SRL and SD2SRL. FIGURE 7 - Powder X-Ray Diffraction Patterns of Pure drug, 
polymers, PM2SRL and SD2SRL.
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Figure 9. PHC and Eudragit polymers have quite different 
morphological characteristics. PHC appeared as irregular 
and three-dimensional crystals with smooth surfaces and 
homogeneous size. The combination of Eudragit S100 + 
RL100 (0.5 + 1.0), SEM analysis revealed the presence 
of rhomboidal shape crystals with different dimensions. 
The physically-mixed and the freeze-dried systems were 
characterized by the presence of unmodified particles of 
Eudragit polymers, which were mechanically covered by 
few crystals of drug. This phenomenon was more evident 
in the freeze-dried system, where it was more difficult to 
detect the features of the crystals of both components, 
appearing as only one type of granule. This behavior 
could be explained by the partial solubilization of Eudragit 
polymers, which improves the adhesion of PHC crystals 
to its surface. A remarkable change in the morphology of 
the materials was shown in the spray-dried system. The 
spray-drying technique yielded products of amorphous 
appearance, with the presence of particles, partially 
broken, of a typical spherical shape and a smooth surface 
with some fissures in the coating layer. The formation of 
aggregates of these spherical particles was also observed. 
In fact, the physical appearance, morphology and size of 
the spray-dried product were completely different from 
those of the mother products, and it was not possible to 
differentiate the distinctive crystals of PHC and Eudragit 
polymers. These observations, although scarcely conclusi-
ve, lead us to predict the existence of a single phase in the 
spray-dried preparation and, consequently, the formation 
of a dispersion system.
Stability studies
The stability data of extended release spray-dried 
solid dispersion capsules (SD2SRL capsules) are presen-
ted in Table 5. The results obtained in the stability test 
showed that the drug content and release rate of PHC 
from SD2SRL capsule formulation, stored at a tempera-
ture of 40 °C ± 1 °C and a relative humidity of 75%, was 
unchanged during three months of accelerating condition 
storage. It was indicated that solid dispersion incorporated 
in capsule formulation was stable, probably due to the fact 
that the stable excipients such as, Lactose, Explotab® and 
Aerosil® were employed in the preparation process of cap-
sules; another reason was that the excipients contributed 
towards protecting the dispersion state of the drug.
CONCLUSION
The solubility of PHC was markedly decreased after 
formation of polymeric dispersions. RL100 had greater 
capacity to adsorb drug as compared to S100 in phosphate 
buffer pH 7.4. The analysis by FT-IR, FT-NMR suggested 
the possibility of hydrogen bonding, whereas the results 
of DSC, PXRD and SEM studies revealed the reduction 
in crystallinity of pure drug in solid dispersions associated 
with diluting effect of polymer. The results also revealed 
FIGURE 8 - 1H-NMR Spectra of Pure drug, polymers, PM2SRL 
and SD2SRL.
FIGURE 9 - SEM Images of Pure drug, polymers, PM2SRL 
and SD2SRL.
Extended release promethazine HCl using acrylic polymers 839
that the preparation conditions did not create significant 
polymorphic changes or amorphization of drug within 
the polymer network. The release of highly water-soluble 
PHC can not be controlled at lower polymer ratios, but was 
markedly sustained in spray-dried solid dispersions using 
RL100 at a higher ratio following better fit-to-zero order 
release kinetics. Eudragit polymers customize release 
profiles when used in combination, and could be success-
fully incorporated to formulate extended release capsules. 
The study provides better forecasting and understanding 
of the particulate systems to be incorporated to develop 
delivery systems.
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